Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Overview | 7 | 1 |
| Therapeutics Development | 8 | 3 |
| Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Products under Development by Stage of Development | 8 | 1 |
| Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Products under Development by Therapy Area | 9 | 1 |
| Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Products under Development by Indication | 10 | 1 |
| Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Products under Development by Companies | 13 | 2 |
| Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Products under Development by Universities/Institutes | 15 | 2 |
| Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Therapeutics Assessment | 17 | 5 |
| Assessment by Monotherapy/Combination Products | 17 | 1 |
| Assessment by Mechanism of Action | 18 | 1 |
| Assessment by Route of Administration | 19 | 2 |
| Assessment by Molecule Type | 21 | 1 |
| Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Companies Involved in Therapeutics Development | 22 | 6 |
| Advinus Therapeutics Ltd | 22 | 1 |
| Johnson &Johnson | 23 | 1 |
| MAKScientific, LLC | 24 | 1 |
| Midatech Pharma US Inc. | 25 | 1 |
| Takeda Pharmaceutical Company Limited | 26 | 1 |
| Zynerba Pharmaceuticals, Inc. | 27 | 1 |
| Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Drug Profiles | 28 | 15 |
| AM-3506 Drug Profile | 28 | 1 |
| AM-5206 Drug Profile | 29 | 1 |
| IPI-940 Drug Profile | 30 | 1 |
| JNJ-40413269 Drug Profile | 31 | 1 |
| KRN-5500 Drug Profile | 32 | 3 |
| Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy Drug Profile | 35 | 1 |
| Small Molecule to Inhibit FAAH for Pain Drug Profile | 36 | 1 |
| Small Molecules to Inhibit COX and FAAH for Oncology, Immunology and CNS Disorders Drug Profile | 37 | 1 |
| URB-694 Drug Profile | 38 | 1 |
| URB-937 Drug Profile | 39 | 1 |
| ZYN-002 Drug Profile | 40 | 3 |
| Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Dormant Projects | 43 | 2 |
| Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Discontinued Products | 45 | 1 |
| Fatty Acid Amide Hydrolase (Oleamide Hydrolase 1 or Anandamide Amidohydrolase or FAAH or EC 3.5.1.99) Featured News &Press Releases | 46 | 11 |
| Sep 06, 2016: Zynerba Pharmaceuticals Launches Phase 2 Clinical Trial of ZYN002 CBD Gel for Treatment of Osteoarthritis | 46 | 1 |
| Aug 01, 2016: Zynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 CBD Gel in Adult Epilepsy Patients with Refractory Focal Seizures | 46 | 1 |
| Jun 27, 2016: Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initiation of Phase 2 Study in Adult Epilepsy Patients with Refractory Focal Seizures | 47 | 1 |
| Apr 12, 2016: Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid | 48 | 1 |
| Feb 25, 2016: Zynerba Pharmaceuticals Announces ZYN002 Granted Orphan Drug Designation for Fragile X Syndrome | 49 | 1 |
| Jan 06, 2016: Zynerba Pharmaceuticals Announces Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial | 49 | 1 |
| Oct 20, 2015: Zynerba Pharmaceuticals Initiates Phase 1 Clinical Trial for ZYN002 CBD Gel | 50 | 1 |
| Jun 16, 2014: DARA BioSciences' KRN5500 Granted Orphan Drug Designation by FDA for Treatment of Multiple Myeloma | 50 | 1 |
| Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA | 51 | 1 |
| Nov 29, 2012: Dara BioSciences Submits Orphan Drug Application For KRN5500 To FDA | 52 | 1 |
| May 09, 2012: Dara To Advance Development Of KRN5500 For Treatment Of Cancer And Neuropathic Pain | 52 | 1 |
| Oct 10, 2011: DARA BioSciences Announces KRN5500 Demonstrated Significant Decrease In Intensity Of Neuropathic Pain In Patients With Cancer | 53 | 1 |
| Sep 15, 2011: DARA BioSciences To Present Positive Results Of KRN5500 Phase II Study At 5th Annual Therapeutics Summit | 54 | 1 |
| Aug 18, 2011: DARA BioSciences Receives Fast Track Designation From FDA For KRN5500 For Treatment Of Chemotherapy-Induced Neuropathic Pain In Patients With Cancer | 55 | 1 |
| Jun 01, 2011: Infinity To Provide Update On IPI-940 | 55 | 2 |
| Appendix | 57 | 2 |
| Methodology | 57 | 1 |
| Coverage | 57 | 1 |
| Secondary Research | 57 | 1 |
| Primary Research | 57 | 1 |
| Expert Panel Validation | 57 | 1 |
| Contact Us | 57 | 1 |
| Disclaimer | 58 | 1 |
